Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Wnt5a protein acts on tumor-surface proteins to accelerate spread of CLL cells

Building upon previous research, scientists at University of California, San Diego School of Medicine and UC San Diego Moores Cancer report that a protein called Wnt5a acts on a pair of tumor-surface proteins, called ROR1 and ROR2, to accelerate the proliferation and spread of chronic lymphocytic leukemia (CLL) cells, the most common form of blood cancer in adults.

22 Dec 2015

Immunotherapy more effective than chemotherapy in treating patients with advanced lung cancer

A new study has found immunotherapy to be more effective than chemotherapy in treating most previously treated patients with advanced lung cancer, and demonstrated effectiveness in a wider population of people than previously known to benefit from the therapy.

22 Dec 2015

Targeted alpha therapy has potential to reduce HIV-infected cells from central nervous system

Targeted alpha therapy has the potential to selectively eliminate HIV infected cells from the central nervous system, according to a recent study co-authored by the JRC. The study shows that a specific human antibody labelled with the alpha emitter bismuth-213 can penetrate the blood brain barrier and selectively target and destroy HIV-infected cells while sparing non-infected healthy cells.

21 Dec 2015

GeNeuro initiates GNbAC1 Phase IIb study in Relapsing-Remitting Multiple Sclerosis

GeNeuro SA, a pioneer of new therapies for neurology and autoimmune disorders, announced today that it has initiated its planned Phase IIb study “CHANGE-MS” (Clinical trial assessing the HERV-W Env ANtagonist GNbAC1 for Efficacy in Multiple Sclerosis) with its lead antibody GNbAC1 in Relapsing-Remitting Multiple Sclerosis (RRMS).

21 Dec 2015

MorphoSys implements Dotmatics’ Vortex to improve antibody research

Dotmatics, a leading provider of scientific informatics solutions and services, announced MorphoSys will implement Vortex to analyse and visualise their screening data enabling rapid, informed decision making. MorphoSys choose Vortex because of the intuitive nature of the product and its extensive drug discovery capabilities.

21 Dec 2015

Novel strategies on the way for difficult-to-treat head and neck cancer

Novel strategies are on the way for difficult-to-treat and advanced head and neck cancer, the most heterogeneous group of malignancies which are generally associated with poor survival, and encouraging results have been presented at the first ESMO Asia 2015 Congress in Singapore.

17 Dec 2015

UMMS researchers identify new life cycle stage in HIV infection

Researchers at the University of Massachusetts Medical School have identified a new life cycle stage in HIV infection, thanks to a novel technique they developed to take images of intact infected cells.

17 Dec 2015

TSRI scientists track how HIV-fighting antibodies develop over time

In a new study, a team led by scientists at The Scripps Research Institute tracked how a family of these HIV-fighting antibodies develops over time. The research shows how a future vaccine might trigger the immune system to produce these antibodies more effectively.

16 Dec 2015

Prophylaxis treatment can protect children who receive liver transplants from HBV-infected donors

Researchers have found that a prophylaxis treatment can prevent new-onset hepatitis B in children who receive liver transplants from donors who were previously infected with hepatitis B virus (HBV) but had successfully cleared the virus.

16 Dec 2015

Molecular signatures can predict flu vaccine responses in young and old

What factors inhibit strong responses to seasonal flu vaccines in the elderly? Why do anti-flu antibodies last longer after vaccination in some people? Answers are emerging from an Emory University-based systems biology analysis of blood samples from more than 400 volunteers who received seasonal flu vaccines. Bali Pulendran, PhD, led a team of researchers who tracked patterns of gene expression, known as molecular signatures, of strong immune responses in volunteers' blood across five consecutive seasons from 2007 to 2011.

16 Dec 2015

Complix signs agreement with Selexis to advance production of autoimmune drug candidate CMX-02

Complix NV, a biopharmaceutical company developing a pipeline of transformative protein therapeutics, called Alphabodies, for the treatment of cancer and severe autoimmune diseases, announces that it is advancing the development of CMX-02, a potential treatment of severe autoimmune disease.

14 Dec 2015

New rapid test can detect malaria parasites, viruses and biomarkers

Nothing could be simpler: a drop of blood is placed on a special carrier substance; after a wait of a few minutes, the slide is placed on a device that emits polarised light thanks to an inexpensive polarisation filter. It is covered with a lid containing a second polarisation filter, which blocks the light from all materials except crystalline or materials with directional properties.

13 Dec 2015

Abbott, UCSF identify human pegivirus 2 among some patients with hepatitis C

Abbott and University of California San Francisco published research identifying a newly discovered human virus, known as human pegivirus 2 (HPgV-2), and proving it is found among some patients with hepatitis C (HCV).

12 Dec 2015

Early life exposures to toxic chemicals reduce infants' response to TB vaccine

Early life exposures to toxic chemicals such as PCBs and DDT dampen an infant's response to the tuberculosis vaccine, according to a new study from the University of Rochester Environmental Health Sciences Center.

11 Dec 2015

Scientists find effective antiviral mechanisms to inhibit chikungunya virus

Scientists looking at the antiviral mechanisms of two previously identified human monoclonal antibodies have found they potently inhibit chikungunya virus (CHIKV) at multiple stages of infection.

11 Dec 2015

Ajinomoto Althea expands biological drug product manufacturing operations

Ajinomoto Althea, Inc., a leading provider of biopharmaceutical contract development and manufacturing services, recently announced it is expanding its existing biological drug product manufacturing operations to include highly active materials such as Antibody Drug Conjugates (ADCs).

10 Dec 2015

Lilly, Merck announce another immuno-oncology collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types.

10 Dec 2015

Monoclonal antibody reduces relapse rate by 18% in postmenopausal, HR-positive breast cancer patients

Giving a monoclonal antibody (denosumab) as adjuvant therapy with aromatase inhibitors in postmenopausal, hormone-receptor-positive breast cancer patients reduces the relapse rate by 18%. This is the central finding of the ABCSG 18 breast cancer study regarding disease-free survival.

10 Dec 2015

Bionomics plans to launch BNC210 Phase 2 trial for treatment of PTSD

Australian drug development company Bionomics Limited will launch a key Phase 2 trial of its novel anxiety drug BNC210 as a treatment for post-traumatic stress disorder (PTSD), following a US$12 million private placement to US institutional investors.

8 Dec 2015

BioAtla, Pfizer sign license and option agreement for new class of antibody therapeutics

BioAtla LLC, a biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into a license and option agreement with Pfizer Inc. to advance the development and commercialization of a new class of antibody therapeutics based on BioAtla's CAB platform and utilizing Pfizer's proprietary antibody drug conjugate (ADC) payloads.

8 Dec 2015